





		EMLc	Codes ATC: J01MA02
Indication	Infectious gastroenteritis or colitis without specification of infectious agent Code ICD11: 1A70.Z		
INN	Ciprofloxacin		
Type de médicament	Chemical agent		
Groupes d'antibiotiques	 WATCH		
Type de liste	Liste de base (EML) (EMLc)		
Formulations	Parenteral > General injections > IV: 2 mg per mL (as hyclate) (EMLc) Oral > Liquid: 250 mg per 5 mL (anhydrous) (EMLc) Oral > Solid > dosage form: 250 mg (as hydrochloride) ; 500 mg (as hydrochloride) (EML) ; 100 mg (as hydrochloride) (EMLc)		
Historique des statuts LME	Ajouté pour la première fois en 2017 (TRS 1006) Modifié en 2021 (TRS 1035) Modifié en 2023 (TRS 1049)		
Sexe	Tous		
Âge	Aussi recommandé pour les enfants		
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique		
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets. 		
Wikipédia	Ciprofloxacin 		
DrugBank	Ciprofloxacin 		

Recommandation du comité d'experts

In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - replacing the oral liquid formulation of azithromycin (200 mg/5 mL) with powder for oral liquid 200 mg/5 mL on the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ciprofloxacin (solid oral dosage form 100 mg (as hydrochloride)) to the EMLc. - the addition of a new strength formulation of sulfamethoxazole + trimethoprim (dispersible tablet 100 mg + 20 mg) on the EMLc.

Recommandations de la LME : Infectious gastroenteritis or colitis without specification of infectious agent

Premier choix

Second choix

ciprofloxacin

cefixime

azithromycin

sulfamethoxazole + trimethoprim

ceftriaxone

